within Pharmacolibrary.Drugs.ATC.A;

model A12CC09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A12CC09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Magnesium orotate is a magnesium salt of orotic acid, used as a dietary supplement to provide magnesium. It has been explored for possible use in cardiovascular conditions (e.g., arrhythmias, heart failure), but it is not widely approved for medical use and is considered a supplement rather than a registered medication in most countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for magnesium orotate in healthy adult individuals, based on general data about oral magnesium formulations as no specific published PK model for magnesium orotate is available.</p><h4>References</h4><ol><li><p>Classen, HG (2004). Magnesium orotate--experimental and clinical evidence. <i>Romanian journal of internal medicine = Revue roumaine de medecine interne</i> 42(3) 491–501. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16366126/\">https://pubmed.ncbi.nlm.nih.gov/16366126</a></p></li><li><p>Verma, H, &amp; Garg, R (2022). Development of a bio-relevant pH gradient dissolution method for a high-dose, weakly acidic drug, its optimization and IVIVC in Wistar rats: a case study of magnesium orotate dihydrate. <i>Magnesium research</i> 35(3) 88–95. DOI:<a href=\"https://doi.org/10.1684/mrh.2022.0505\">10.1684/mrh.2022.0505</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36861812/\">https://pubmed.ncbi.nlm.nih.gov/36861812</a></p></li><li><p>Verma, H, &amp; Garg, R (2021). Development, optimization and characterization of chewable tablet containing synergistic combination of magnesium orotate dihydrate with cholecalciferol and menaquinone-7 for management of hyperglycemia and its pharmacokinetic study. <i>Magnesium research</i> 34(2) 43–63. DOI:<a href=\"https://doi.org/10.1684/mrh.2021.0487\">10.1684/mrh.2021.0487</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34463282/\">https://pubmed.ncbi.nlm.nih.gov/34463282</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A12CC09;
